ArticleBMC health services research2026
Economic burden of MDR/RR-TB and implementation of a treatment subsidy policy in Lishui City, China: a retrospective study following strobe guidelines.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) imposes significant financial burdens on patients. This study aimed to examine the current status of the economic burden of disease in patients with MDR/RR-TB in Lishui City, Zhejiang Province, and to describe the actual implementation status of the diagnosis-and-treatment subsidy policy and explore associations between subsidy indicators and patient treatment outcomes.
methodsWe conducted a retrospective survey of 117 MDR/RR-TB patients diagnosed and managed in Lishui City from 2017 to 2022. Data on sociodemographic characteristics, diagnosis and treatment processes, medical expenses, and subsidy information were collected and analyzed using questionnaires.
resultsThe median direct medical expenses (DME) for the 117 patients were Chinese yuan (RMB) 65,182.66 (1 RMB = 0.14 USD). The median amount reimbursed by medical insurance was RMB 40,223.33, and the median out-of-pocket (OOP) payments after medical insurance reimbursement were RMB 21,938.82. The median subsidy amount was RMB 14,405.45, resulting in final OOP payments of RMB 8,167.13. Patients using bedaquiline, linezolid, and clofazimine received higher subsidies compared to non-users (P < 0.05). Logistic regression analysis showed that subsidy amounts below RMB 14,405.45 were significantly associated with adverse treatment outcomes (95%CI: 0.046-0.534, OR = 0.157, P = 0.003). The overall treatment success rate was 75.21%.
conclusionMDR/RR-TB patients face a significant economic burden. The findings suggest that the subsidy policy may contribute to reducing out-of-pocket expenditures among MDR/RR-TB patients; however, further studies using stronger analytical designs are needed to evaluate its effectiveness. Optimizing subsidy criteria, raising subsidy levels and streamlining reimbursement procedures may help relieve patient financial stress, yet relevant benefits require verification via high-quality research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.